Veru (NASDAQ:VERU) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Veru (NASDAQ:VERU) released its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. Veru had a negative net margin of 223.85% and a negative return on equity of 92.88%.

Veru Stock Down 8.0 %

Shares of NASDAQ:VERU traded down $0.04 during trading on Thursday, reaching $0.51. 4,007,623 shares of the company traded hands, compared to its average volume of 5,243,357. The company’s 50 day moving average is $0.72 and its two-hundred day moving average is $0.77. Veru has a 52 week low of $0.37 and a 52 week high of $1.92. The firm has a market capitalization of $74.07 million, a PE ratio of -1.80 and a beta of -0.54.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reaffirmed an “outperform” rating and set a $5.00 price target on shares of Veru in a report on Tuesday, November 5th.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.